Oral prednisolone ( DrugBank: Prednisolone )

3 diseases

49. 全身性エリテマトーデス

臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01773616 (ClinicalTrials.gov)	April 2015	1/11/2012	Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis	Phase 3 Open Label Randomised Multicentre Controlled Trial of Rituxmab and Mycophenolate Mofetil Without Oral Steroids for the Treatment of Lupus Nephritis	Systemic Lupus Erythematosus, Lupus Nephritis	Drug: Oral prednisolone;Drug: Rituximab;Drug: Mycophenolate mofetil;Drug: Methyl prednisolone	Imperial College London	Karolinska Institutet;Ohio State University;Dutch Working Party on Systemic Lupus Erythematosus;EULAR Lupus Nephritis Trial Network Study Group	Terminated	12 Years	75 Years	All	24	Phase 3	United Kingdom
2	JPRN-UMIN000000639	2007/03/01	16/03/2007	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III study of Rituximab in Patients with Systemic Lupus Erythematosus		Systemic lupus erythematosus	IDEC-C2B8 plus oral prednisolone(tapering) 1000 mg of IDEC-C2B8 on days 1 and 15.Repeated at an interval of 6 months (Days 169 and 183). Placebo plus oral prednisolone(tapering) 1000 mg of placebo day 1 and 15.Repeated at an interval of 6 months (Days 169 and 183).	Zenyaku Kogyo Co., Ltd.	NULL	Complete: follow-up complete	16years-old	75years-old	Male and Female	150	Phase 2/3	Japan

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05284136 (ClinicalTrials.gov)	April 1, 2022	28/2/2022	Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease	Prospective rAndomized Controlled tRial of Crohn's diseAse Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease - PARADISE	Crohn Disease	Dietary Supplement: Crohn's disease exclusion diet (CDED);Drug: Oral prednisolone	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	16 Years	70 Years	All	80	Phase 2/Phase 3	France;Netherlands

臨床試験数 : 43 / 薬物数 : 54 - (DrugBank : 15) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03876444 (ClinicalTrials.gov)	April 1, 2019	12/3/2019	Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms	Intravenous Methylprednisolone Versus High Dose Oral Prednisolone for the Treatment of Infantile Spasms: a Randomized Open-labelled Trial	Infantile Spasm	Drug: Intravenous Methylprednisolone;Drug: Oral Pednisolone	Suvasini Sharma	NULL	Recruiting	4 Months	30 Months	All	128	Phase 2/Phase 3	India
2	NCT01575639 (ClinicalTrials.gov)	February 2012	9/4/2012	Prednisolone in Infantile Spasms- High Dose Versus Usual Dose	Randomized Trial of High Dose (4mg/kg) Versus Usual Dose (2mg/kg) Oral Prednisolone in the Treatment of Infantile Spasms.	Infantile Spasms;West Syndrome	Drug: Oral prednisolone	Lady Hardinge Medical College	NULL	Completed	3 Months	24 Months	Both	63	Phase 3	India